Chi Wang
Impact in
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Molecular Biology top 10%
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
Papers in
-
- Ubiquitin and proteasome pathways 5
- Epigenetics and DNA Methylation 4
- Wnt/β-catenin signaling in development and cancer 3
- Oncology 13
- Drug Transport and Resistance Mechanisms 4
- Cancer Cells and Metastasis 3
- Co-authors
- Daheng He (10 shared papers)Tianyan Gao (7 shared papers)B. Mark Evers (11 shared papers)Hui Yu (1 shared paper)Xiaoyu Cui (1 shared paper)Moumita Banerjee (1 shared paper)Zijian Xie (1 shared paper)Liquan Cai (1 shared paper)
- Journals
- Cancer Research (4 papers)Nature Communications (4 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)PLoS ONE (3 papers)Oncogene (2 papers)
- Partner nations
- United StatesChinaSpain
In The Last Decade
Chi Wang
51 papers receiving 2.2k citations
Chi Wang's Hit Papers
Peers
Comparison fields: 5 of 163
- Cancer Research 364
- Molecular Biology 1.1k
- Oncology 350
- Cell Biology 130
- Immunology 135
Countries citing papers authored by Chi Wang
This map shows the geographic impact of Chi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi Wang more than expected).
Fields of papers citing papers by Chi Wang
This network shows the impact of papers produced by Chi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi Wang. The network helps show where Chi Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Chi Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Na/K-ATPase Y260 Phosphorylation–mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth Hit paper breakdown → | 2018 | 492 |
| 2 | 2013 | 146 | |
| 3 | 2017 | 119 | |
| 4 | 2020 | 91 | |
| 5 | 1999 | 83 | |
| 6 | 2020 | 82 | |
| 7 | 2020 | 75 | |
| 8 | 2014 | 74 | |
| 9 | 2019 | 71 | |
| 10 | 2018 | 65 | |
| 11 | 2012 | 62 | |
| 12 | 2018 | 60 | |
| 13 | 2014 | 59 | |
| 14 | 2017 | 51 | |
| 15 | 2017 | 38 | |
| 16 | 2022 | 38 | |
| 17 | 2017 | 38 | |
| 18 | 2015 | 37 | |
| 19 | 2018 | 35 | |
| 20 | 2020 | 35 |
About Chi Wang
Chi Wang is a scholar working on Molecular Biology, Oncology, Cancer Research, Physiology and Pulmonary and Respiratory Medicine, having authored 53 papers that have together received 2.2k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (5 papers), Prostate Cancer Treatment and Research (5 papers), Epigenetics and DNA Methylation (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), Cancer Cells and Metastasis (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Hippo pathway signaling and YAP/TAZ (3 papers). The work is most often cited by research in Cancer Research (364 citations), Molecular Biology (1.1k citations), Oncology (350 citations), Cell Biology (130 citations) and Immunology (135 citations). Chi Wang has collaborated with scholars based in United States, China and Spain. Frequent co-authors include Daheng He, Tianyan Gao, B. Mark Evers, Hui Yu, Xiaoyu Cui, Moumita Banerjee, Zijian Xie, Liquan Cai, Zhichuan Li and Yekaterina Y. Zaytseva. Their work appears in journals such as Cancer Research, Nature Communications, Journal of Pharmacology and Experimental Therapeutics, PLoS ONE and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.